DoH Policies screened during the period: 1st January 2020-31st March 2020
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (PDF 334KB)
- NICE Technology Appraisal TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (PDF 334KB)
- NICE Technology Appraisal TA616 - Cladribine for treating relapsing–remitting multiple sclerosis (review of TA493) (PDF 377KB)
- NICE Technology Appraisal TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (PDF 335KB)
- NICE Technology Appraisal TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (PDF 333KB)
- NICE Technology Appraisal TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (review of TA381) (PDF 335KB)
- NICE Technology Appraisal TA621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (PDF 336KB)
- NICE Clinical Guideline NG121 - Intrapartum care for women with existing medical conditions or obstetric complications and their babies (PDF 333KB)
- NICE Clinical Guideline NG122 - Lung cancer: diagnosis and management (updates and replaces CG121) (PDF 331KB)
- NICE Technology Appraisal TA622 - Sotagliflozin with insulin for treating type 1 diabetes (PDF 379KB)
- NICE Technology Appraisal TA623 - Patiromer for treating hyperkalaemia (PDF 376KB)
- NICE Technology Appraisal TA624 - Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (PDF 441KB)